October 2014 Br J Cardiol 2014;21:146 Online First
Drs Usha Rao and Simon C Eccleshall
Dear Sirs, Ischaemic heart disease (IHD) is a major cause of mortality and morbidity, and percutaneous coronary intervention (PCI) is a mainstay of treatment. The management of IHD has been revolutionised by major advancements in the field of coronary angioplasty, starting with the use of balloons for percutaneous transluminal coronary angioplasty (PTCA) in 1977 by Gruentzig.1 However, their use was limited by acute recoil (approximately 40%), vessel dissection and a high re-stenosis rate (50%). To treat the acute problems of recoil and dissection (with acute vessel closure) and reduce the rate of re-stenosis, coronary stents were introduced
March 2010 Br J Cardiol 2010;17:64-6
Michael Norell
So there I was, sitting in one of our twice-weekly multi-disciplinary team (MDT) meetings. I was proffering my sixpence worth on the merits of surgery (coronary artery bypass graft [CABG]) or percutaneous coronary intervention (PCI) (occasionally neither, and – rarely – both), as a succession of clinical data, scans of various types and coronary angiograms were laid before us. And I got to thinking, “is this the way it should be?” We have come a long way in tailoring treatment to patients. When PCI, or percutaneous transluminal coronary angioplasty (PTCA) as it was then, emerged as a young and promising technique in the late seventies
March 2006 Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 22–AIC 25
Guido Materazzo, Davide Ghitti, Marco Rossi, Giuseppe Nasso, Paola Spatuzza, Carlo Maria De Filippo, Pietro Modugno, Amedeo Anselmi, Francesco Alessandrini
No content available
September 2002 Br J Cardiol 2002;9:476-7
Khaled Alfakih, Alistair Hall, Mike Robinson
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits